My initial reaction is *&#$@, didn't expect that, and have no...

My initial reaction is *&#$@, didn't expect that, and have no idea how this plays out.

I hope that management has the best interests of minor shareholders at heart - one of the reasons I have invested in this company is that it has always seemed to be well governed.

Not going to speculate on what might happen, not my area of experience.

I do think though this action is driven by the potential of the product and the very positive position we are in with the RCT:

• Very impressive results after 1 year, particularly on the adjusted (FDA relevant) results
• Very low statistical probability that the two year results won't fall into line given the real world data already shows what is likely to happen.
• Company would already know the 2 year results
• All the above positions Naturalvue considerably in front of the only alternative soft lens Misight
• Misight sales have grown from roughly $2M to > $20M after FDA approval in 3 years, proving the market exists, and Cooper Companies recently doubled their Misight sales group in the US.

My interest is staying in if I can, subject to whatever we are presented with. Have no idea what that may look like.